Ad is loading...
BASVX
Price
$13.55
Change
-$0.11 (-0.81%)
Updated
Nov 15 closing price
RMFCX
Price
$58.23
Change
-$0.50 (-0.85%)
Updated
Nov 15 closing price
Ad is loading...

BASVX vs RMFCX

Header iconBASVX vs RMFCX Comparison
Open Charts BASVX vs RMFCXBanner chart's image
Brown Advisory Sustainable Val Inst
Price$13.55
Change-$0.11 (-0.81%)
VolumeN/A
CapitalizationN/A
American Funds American Mutual R3
Price$58.23
Change-$0.50 (-0.85%)
VolumeN/A
CapitalizationN/A
BASVX vs RMFCX Comparison Chart
Loading...
View a ticker or compare two or three
VS
BASVX vs. RMFCX commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BASVX is a StrongBuy and RMFCX is a StrongBuy.

FUNDAMENTALS
Fundamentals
RMFCX has more cash in the bank: 104B vs. BASVX (126M). RMFCX pays higher dividends than BASVX: RMFCX (1.69) vs BASVX (0.88). BASVX was incepted earlier than RMFCX: BASVX (2 years) vs RMFCX (22 years). RMFCX is a more actively managed with annual turnover of: 25.00 vs. BASVX (11.00). RMFCX has a lower initial minimum investment than BASVX: RMFCX (250) vs BASVX (1000000). BASVX annual gain was more profitable for investors over the last year : 32.61 vs. RMFCX (21.31).
BASVXRMFCXBASVX / RMFCX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence2 years22 years-
Gain YTD22.40316.440136%
Front LoadN/AN/A-
Min. Initial Investment1000000250400,000%
Min. Initial Investment IRAN/AN/A-
Net Assets126M104B0%
Annual Yield % from dividends0.881.6952%
Returns for 1 year32.6121.31153%
Returns for 3 yearsN/A15.46-
Returns for 5 yearsN/A44.92-
Returns for 10 years39.3065.0160%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MNTS0.630.01
+1.10%
Momentus
WWW21.79-0.24
-1.09%
Wolverine World Wide
SNAP10.60-0.16
-1.49%
Snap
SHC14.31-0.68
-4.54%
Sotera Health Company
ENTA9.53-0.60
-5.92%
Enanta Pharmaceuticals